Want to see SE:VIVE full AI Analyst Report?
Top Page
Vivesto AB
(VIVE)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr7.00
▲(8650.00% Upside)
Action:Reiterated
Date:10/08/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and negative operating/free cash flow) and bearish technicals (price below key moving averages and negative MACD). A relatively strong, low-leverage balance sheet provides some support, but valuation remains hard to justify on earnings given the negative P/E.
Positive Factors
Low leverage and equity cushion
A debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Negative Factors
Near-zero revenue base
Near-zero reported revenue shows that Vivesto has not yet established a recurring commercial business capable of funding operations. Until a candidate is approved, partnered on meaningful terms, or commercialized, financial performance remains heavily dependent on development progress and available capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and equity cushion
A debt-free balance sheet and substantial equity cushion give Vivesto greater financial flexibility than a highly leveraged development-stage biotech. This can support continued research investment and help absorb operating losses, although preserving that cushion depends on improving operations or securing funding.
Read all positive factors
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr79.27M
Dividend YieldN/A
Average Volume (3M)7.55K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth32.62%
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.79
Shares Outstanding11,071,369
10 Day Avg. Volume7,190
30 Day Avg. Volume7,547
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.06
Revenue Forecast (FY)N/A
Vivesto AB Business Overview & Revenue Model
Company Description
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. I...
How the Company Makes Money
Vivesto AB’s revenue model is primarily that of a development-stage biopharmaceutical company: it seeks to create shareholder value and future earnings by advancing oncology drug candidates through preclinical and clinical development toward regul...
Vivesto AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 26.19M |
| Gross Profit | -478.00K | 0.00 | -3.19M | 0.00 | -10.66M | -17.93M |
| EBITDA | -31.00M | -34.38M | -36.56M | -123.79M | -100.56M | -99.77M |
| Net Income | -31.54M | -34.08M | -39.75M | -128.74M | -367.03M | -138.94M |
Balance Sheet | ||||||
| Total Assets | 168.56M | 149.04M | 172.88M | 220.67M | 355.88M | 594.31M |
| Cash, Cash Equivalents and Short-Term Investments | 23.51M | 2.10M | 32.29M | 77.04M | 142.51M | 97.27M |
| Total Debt | 0.00 | 13.00M | 0.00 | 0.00 | 8.17M | 10.43M |
| Total Liabilities | 10.30M | 24.46M | 14.55M | 22.87M | 30.45M | 44.59M |
| Stockholders Equity | 158.26M | 124.58M | 158.33M | 197.80M | 325.42M | 549.71M |
Cash Flow | ||||||
| Free Cash Flow | -24.64M | -43.81M | -47.25M | -69.40M | -80.79M | -179.91M |
| Operating Cash Flow | -29.64M | -33.96M | -47.25M | -68.74M | -80.52M | -145.56M |
| Investing Cash Flow | -18.55M | 21.85M | 43.40M | 63.73M | -45.28M | 118.65M |
| Financing Cash Flow | 48.94M | 13.00M | 0.00 | 0.00 | 128.76M | -5.81M |
Vivesto AB Technical Analysis
Negative
0.08
Price Trends
8.76
Negative
9.06
Negative
9.00
Negative
Market Momentum
-0.37
Positive
21.95
Positive
9.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIVE, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 8.60, below the 50-day MA of 8.76, and below the 200-day MA of 9.00, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 21.95 is Positive, neither overbought nor oversold. The STOCH value of 9.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIVE.
Vivesto AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr92.06M | 0.80 | 23.67% | ― | 163.58% | ― | |
52 Neutral | kr2.16B | -85.25 | -22.38% | ― | 104.76% | 37.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr84.63M | -2.15 | -106.23% | ― | -97.37% | 25.28% | |
42 Neutral | kr79.27M | -9.40 | -21.64% | ― | ― | 32.62% | |
41 Neutral | kr23.68M | -0.13 | -57.15% | ― | ― | 16.02% | |
38 Underperform | kr87.82M | -1.33 | -66.41% | ― | -47.42% | 44.01% |
* Healthcare Sector Average
SE:VIVE
Vivesto AB
7.16
-12.95
-64.39%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
1.81
-7.70
-80.97%
SE:SPEC
SpectraCure AB
0.02
-0.13
-89.04%
SE:NICA
Nanologica AB
0.28
-0.87
-75.63%
SE:SPAGO
Spago Nanomedical AB
0.11
>-0.01
-7.83%
SE:NANEXA
Nanexa AB
11.30
9.17
430.52%
Vivesto AB Corporate Events
Vivesto’s Paccal Vet Data Spotlighted at Key Veterinary Oncology Conference
Sep 24, 2026
Vivesto AB announced that topline data from its Paccal Vet clinical studies in dogs and cats are being presented in two posters at the Veterinary Cancer Society Annual Conference 2026 in Minneapolis, reinforcing the company’s growing presenc...
Vivesto’s Paccal Vet Shows Promising Efficacy and Safety in Feline Cancer Study
Sep 17, 2026
Vivesto AB has reported positive topline results from its dose-finding study of Paccal Vet in cats with solid tumors, showing clear indications of anti-tumor activity across multiple tumor types. The trial enrolled 21 cats and identified biologica...
Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study
Sep 15, 2026
Vivesto AB has reported positive topline results from an open-label pilot study of its veterinary cancer drug candidate Paccal Vet in dogs with Stage I-II splenic hemangiosarcoma following splenectomy. The median overall survival of 135 days excee...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.